The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2019 | POLO: Olaparib as maintenance treatment for metastatic pancreatic cancer

Name: POLO: Olaparib as maintenance treatment for metastatic pancreatic cancer
Uploaded: 2019-06-02T00:00:00Z
Duration: 7 min 50 s
Description: Michael Hall, MD, MS of the Fox Chase Cancer Center, Philadelphia, PA, talks on the key updates from the POLO trial investigating olaparib as maintenance treatment for metastatic pancreatic cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Michael Hall • 2 Jun 2019

ASCO 2019

Gastrointestinal Cancer Pancreatic Cancer Olaparib

POLO

Michael Hall, MD, MS of the Fox Chase Cancer Center, Philadelphia, PA, talks on the key updates from the POLO trial investigating olaparib as maintenance treatment for metastatic pancreatic cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.